Gefitinib versus Docetaxel for Previously Treated NSCLC―Letter

We read with great interest the recent article by Lee and colleagues, reporting the final results of the ISTANA trial ([1][1]). The authors affirm that these results prove the superiority of gefitinib over chemotherapy in the treatment of advanced, pretreated non–small-cell lung cancer (NSCLC) in